Reimagining Pharmaceutical Manufacturing: Why the latest E2500-25 Standard Revision Demands Immediate Action
Speed to patient is a primary driver behind the industry's shift toward modern commissioning and qualification (C&Q) practices, while still ensuring product quality and patient...
Read MoreBalancing Scalability, Speed, and Quality in Pharma Startups
Pharmaceutical companies today face a high-stakes equation: launch faster, meet global demand, and maintain quality and compliance—without fail. That means simultaneously spinning up manufacturing sites,...
Read MoreBuilding the Future of Pharmaceutical Manufacturing: A Phased Approach to Dark Factories
Why Invest in a Dark Factory? Pharmaceutical manufacturers are under increasing pressure to meet growing patient demand, accelerate drug development timelines, and adapt to evolving...
Read MoreEngaging Early: FDA’s Collaborative Pathways for AI in Regulatory Applications (Part 3 of 3)
Nick Armstrong, Senior Director of Digital Enablement at CAI and co-chair of the ISPE Community of Practice on AI, specializes in the intersection of artificial...
Read MoreSustaining Reliability: Life Cycle Maintenance of AI Models in Drug Development (Part 2 of 3)
Nick Armstrong, Senior Director of Digital Enablement at CAI and co-chair of the ISPE Community of Practice on AI, specializes in the intersection of artificial...
Read More